Abbott's once-daily Kaletra for those with lifestyle challenges
This article was originally published in Scrip
Executive Summary
HIV patients whose lifestyle cannot accommodate multiple daily dosing are expected to benefit from the approval of a once-daily dosing regimen for Abbott's Kaletra (lopinavir plus ritonavir) tablets by the European Commission.